alexa Blockade Of Integrin Alpha4 By Natalizumab Sensitizes T-ALL Cells To Chemotherapy
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference on Hematology & Blood Disorders
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Enzi Jiang, Yao-Te Hsieh, Colleen Garvey, Andrea Osborne, Stephanie Shishido, Halvard B?nig and Yong-Mi Kim
Accepted Abstracts: J Blood Disorders Transf
DOI: 10.4172/2155-9864.S1.008
Abstract
Acute lymphoblastic leukemia (ALL) occurs in both children and adults with peak incidence between 2 and 5 years of age. Over the last decades, survival in pediatric ALL has improved to 85%~90% and around 40% in adults. Still the relapse remains major obstacle for the cure of ALL. In our previous study, we demonstrated that integrin alpha4 blockade using natalizumab, a humanized monoclonal antibody against integrin alpha4, reduced adhesion of pre-B ALL cells to bone marrow (BM) stroma and with combination of conventional chemotherapy eliminated resistant pre-B-ALL clones in a MRD mouse model. The present study explored the potential of Natalizumab as a novel T-ALL treatment modality. Natalizumab inhibited adhesion of patient-derived T-ALL cells to BM stroma and attenuated leukemia progression, resulting in prolonged survival of recipient NOD/SCID IL2R gamma-/- mice of patient-derived T-ALL. Integrin alpha4 blockade interferes with adhesion of T-All cells to its ligand VCAM-1 and might be considered as a novel adjuvant strategy against T-ALL. Further study is needed to investigate at the molecular level to elucidate the effect of alpha4 blockade in T-ALL.
Biography
Enzi Jiang received her MD from Norman Bethune College of Medicine, Jilin University, formerly Norman Bethune University of Medical Science, Changchun, China in 1987. She completed her PhD from Harbin Medical University in 1999 and Postdoctoral research from University of Texas Southwestern Medical Center at Dallas in 2007. She is working as a Senior Scientist at Division of Hematology and Oncology, Children?s Hospital Los Angeles University of Southern California Keck School of Medicine, Los Angeles, USA. She has published more than 15 papers in reputed journals related to mesenchymal stem cells and leukemia and contributed to a book chapter (Chapter 4: Molecular Pathogenesis of ALL, Contemporary Management of Acute Lymphoblastic Leukemia, In Press 2014). She has been serving as an Editorial Board Member for the Journal of Blood Disorders and Transfusion since February, 2013. Her research interests include overcoming drug resistance in ALL and related mechanisms.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords